title: Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: E
authors.initials: E
authors.lastname: Berman
authors.forename: V
authors.initials: V
authors.lastname: Raymond
authors.forename: T
authors.initials: T
authors.lastname: Gee
authors.forename: S J
authors.initials: SJ
authors.lastname: Kempin
authors.forename: S
authors.initials: S
authors.lastname: Gulati
authors.forename: M
authors.initials: M
authors.lastname: Andreeff
authors.forename: J
authors.initials: J
authors.lastname: Kolitz
authors.forename: J
authors.initials: J
authors.lastname: Gabrilove
authors.forename: G
authors.initials: G
authors.lastname: Heller
authors.forename: C W
authors.initials: CW
authors.lastname: Young
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects; D007938:Leukemia / Q000188:drug therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin